Showing results (141-150 of 157) with videos related to

Sort By:
Pageof 16
Cancers|July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationMeritxell Bellet, Faten Ahmad, Rafael Villanueva, et al.
Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2025
Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trialCarles Gomà, Meritxell Mollà, Gabriela Oses, et al.
Oncotarget|April 21, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerAranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, et al.
The Lancet. HIV|January 7, 2023
Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensusSara E Croxford, Veronique Martin, Sebastian B Lucas, et al.
Nature Communications|March 1, 2023
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerAleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, et al.
Frontiers in Oncology|May 15, 2023
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancerRubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
Pageof 16